Sight Sciences (SGHT) Stock Price, News & Analysis

Company Overview

Sight Sciences, Inc. is a medical technology company focused on developing and commercializing treatments for common eye diseases. The company’s products are designed to address glaucoma and dry eye disease, with an emphasis on minimally invasive procedures and technologies intended for use by eye-care professionals.

Its glaucoma portfolio includes the OMNI Surgical System, a device used in minimally invasive glaucoma surgery to help reduce intraocular pressure by improving the eye’s natural fluid outflow pathways. Sight Sciences also offers the TearCare System, which is designed to treat meibomian gland dysfunction, a leading cause of evaporative dry eye disease, by applying localized thermal therapy to the eyelids.

Sight Sciences markets its products primarily through ophthalmology and optometry channels in the United States and has expanded its commercial presence into select international markets. The company is headquartered in Menlo Park, California, and its shares trade on the Nasdaq under the symbol SGHT.

Key Stats

• Today's Range: $7.93 to $8.14
• 50-Day Range: $4.70 to $8.55
• 52-Week Range: $3.19 to $9.24
• Volume: 453,199 shs
• Average Volume: 160,777 shs
• Market Capitalization: $441.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.88
• Consensus Rating: Moderate Buy

Sight Sciences Stock Analysis - MarketRank™

Sight Sciences scored higher than 27% of companies evaluated by MarketBeat, and ranked 780th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sight Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Sight Sciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Sight Sciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sight Sciences are expected to grow in the coming year, from ($0.52) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sight Sciences is -14.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sight Sciences is -14.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sight Sciences has a P/B Ratio of 6.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.19% of the float of Sight Sciences has been sold short.

Short Interest Ratio / Days to Cover

Sight Sciences has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Sight Sciences has recently increased by 38.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sight Sciences does not currently pay a dividend.

Dividend Growth

Sight Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.26

News Sentiment

Sight Sciences has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Sight Sciences this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $318,827.00 in company stock.

Percentage Held by Insiders

30.40% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:SGHT
• CIK: 1531177
• Web: www.sightsciences.com
• Phone: 877-266-1144
• Fax: N/A
• Employees: 186
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Sight Sciences: $7.88
• High Price Target: $9.00
• Low Price Target: $6.00
• Potential Upside/Downside: -1.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.43 million
• Net Margins: -35.69%
• Pretax Margin: -35.73%
• Return on Equity: -43.39%
• Return on Assets: -22.86%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 4.95
• Quick Ratio: 4.67

Sales & Book Value

• Annual Sales: $77.36 million
• Price / Sales: 5.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.21 per share
• Price / Book: 6.63

Miscellaneous

• Outstanding Shares: 55,090,000
• Free Float: 38,341,000
• Market Cap: $441.82 million
• Optionable: Optionable
• Beta: 2.50